Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkıran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Boz C, et al. Among authors: sevim s. Neurol Sci. 2023 Jun;44(6):2121-2129. doi: 10.1007/s10072-023-06608-z. Epub 2023 Jan 23. Neurol Sci. 2023. PMID: 36689010
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Boz C, et al. Among authors: sevim s. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. Epub 2019 Aug 26. Mult Scler Relat Disord. 2019. PMID: 31473488
'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'.
Sevim S, Demirkıran M, Terzi M, Yüceyar N, Taşdelen B, İdiman E, Kürtüncü M, Boz C, Tuncel D, Karabudak R, Siva A, Özcan A, Neyal M, Göksel BK, Balal M, Şen S, Ekmekçi Ö, Öksüz N, Kaya D. Sevim S, et al. Mult Scler Relat Disord. 2020 Jul;42:102055. doi: 10.1016/j.msard.2020.102055. Epub 2020 Mar 16. Mult Scler Relat Disord. 2020. PMID: 32473575
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression.
Sevim S, Demirkiran M, Terzi M, Yüceyar N, Taşdelen B, Idiman E, Kürtüncü M, Boz C, Tuncel D, Karabudak R, Siva A, Özcan A, Neyal M, Göksel BK, Gazaloğlu GB, Balal M, Şen S, Baklan MA, Gündüz T, Tuncer A, Uygunoğlu U. Sevim S, et al. Arq Neuropsiquiatr. 2022 Feb;80(2):168-172. doi: 10.1590/0004-282X-ANP-2020-0400. Arq Neuropsiquiatr. 2022. PMID: 35195221 Free PMC article.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Sen S, et al. Among authors: sevim s. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19. Mult Scler Relat Disord. 2022. PMID: 35216782 Free PMC article.
Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Terzi M, Helvacı EM, Şen S, Boz C, Çilingir V, Akçalı A, Beckmann Y, Uzunköprü C, Türkoğlu R, Yüceyar N, Efendi H, Bünül SD, Seferoğlu M, Kotan D, Güler S, Balcı BP, Öztürk B, Mungan S, İçen NK, Ömerhoca S, Yurtoğulları Ş, Sevim S, Türkoğlu ŞA, Çam M, Yetkin MF, Yoldaş TK, Sıvacı AÖ, Gökçe ŞF, Gürsoy E, Ünal A, Bilge N, Ağan K, Toprak MK, Koçer B, Sezer G, Terzi Y. Terzi M, et al. Among authors: sevim s. Noro Psikiyatr Ars. 2023 Jan 13;60(1):23-27. doi: 10.29399/npa.28081. eCollection 2023. Noro Psikiyatr Ars. 2023. PMID: 36911568 Free PMC article.
Erratum: Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment.
Terzi M, Helvacı EM, Şen S, Boz C, Çilingir V, Akçalı A, Beckmann Y, Uzunköprü C, Türkoğlu R, Yüceyar N, Efendi H, Destan Bünül S, Seferoğlu M, Kotan D, Güler S, Balcı BP, Öztürk B, Mungan S, İçen NK, Ömerhoca S, Yurtoğulları Ş, Sevim S, Türkoğlu ŞA, Çam M, Yetkin MF, Yoldaş TK, Sıvacı AÖ, Gökçe ŞF, Gürsoy E, Ünal A, Bilge N, Ağan K, Toprak MK, Koçer B, Sözer G, Terzi Y. Terzi M, et al. Among authors: sevim s. Noro Psikiyatr Ars. 2023 May 25;60(2):190. doi: 10.29399/npa.28499. eCollection 2023. Noro Psikiyatr Ars. 2023. PMID: 37287556 Free PMC article.
79 results